ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

Office: (425) 823-0400
Fax: (425) 823-8508

Close Window

A World Leader in Therapeutics Targeting Misfolded Proteins and Amyloid Diseases

ProteoTech Inc., is a private drug development Company that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting misfolded proteins and amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloid disease (including AL, TTR and AA amyloidosis).

With over 275 issued patents in its intellectual property estate, ProteoTech will soon enter proof-of-concept human clinical trials for its small molecule drug, Systebryl™, for the treatment of AL (immunoglobulin light chain) amyloidosis.

The Company is in late stage pre-clinical development with Synuclere™ for the treatment of Parkinson's disease, and is also in late stage pre-clinical development for a novel small peptide called PeptiClere™ for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of tau protein aggregation seen in tauopathies such as Alzheimer's and progressive supranuclear palsy (PSP.) This latter project is funded by a $2.3M Phase II SBIR (Small Business Innovative research) award from the National Institute on Aging. Lastly, ProteoTech has identified lead compounds that target islet amyloid fibrils present in 90% of patients with Type 2 diabetes.

ProteoTech's Disease Targets
AL Amyloidosis Target:AL Amyloid Protein Alzheimers Target:Beta-amyloid & Tau Protein
ProteoTech's Systemic AA Amyloidosis Target: Systemic AA Amyloidosis ProteoTech's Alzheimers Target: Beta-amyloid Protein
AL Amyloid in heart
(click image to enlarge)
Human Alzheimer's brain filled
with amyloid plaques (arrows)
(click image to enlarge)
Parkinson's Target:Alpha-synuclein Type 2 Diabetes Target:Islet Amyloid Polypeptide
ProteoTech's Parkinson's Target: Alpha-synuclein ProteoTech's Type 2 Diabetes Target: Islet Amyloid Polypeptide
Neuron in the substantia nigra with a
Lewy body containing alpha-synuclein
(click image to enlarge)
Congo red staining of IAPP amyloid
deposits in Islet of Langerhans
(pancreas) of patient with Type 2 Diabetes
(click image to enlarge)